Adhera Therapeutics (ATRX) Short Interest Ratio & Short Volume → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free ATRX Stock Alerts $0.0081 0.00 (0.00%) (As of 05/16/2024 ET) Add Compare Share Share Short InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Adhera Therapeutics Short Interest DataCurrent Short Volume100 sharesPrevious Short Volume2,000 sharesChange Vs. Previous Month-95.00%Dollar Volume Sold Short$1.22Short Interest Ratio / Days to Cover0.0Last Record DateMarch 15, 2024Outstanding Shares11,627,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume1 sharesAverage Trading Volume18,429 sharesToday's Volume Vs. Average0% Short Selling Adhera Therapeutics ? Sign up to receive the latest short interest report for Adhera Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatATRX Short Interest Over TimeATRX Days to Cover Over TimeATRX Percentage of Float Shorted Over Time Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. Adhera Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2024100 shares $1.22 -95.0%N/A0 $0.01 2/29/20242,000 shares $33.60 -85.0%N/A0 $0.02 2/15/202413,300 shares $212.80 No ChangeN/A0 $0.02 1/15/202414,600 shares $271.56 +7,200.0%N/A0 $0.02 12/31/2023200 shares $6.00 No ChangeN/A0 $0.03 11/30/202311,800 shares $179.36 +81.5%N/A0 $0.02 Get the Latest News and Ratings for ATRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/20236,500 shares $71.50 -53.2%N/A0 $0.01 10/31/202313,900 shares $148.73 +286.1%N/A0.1 $0.01 10/15/20233,600 shares $50.40 -59.6%N/A0 $0.01 9/30/20238,900 shares $267.00 +270.8%N/A0.1 $0.03 9/15/20232,400 shares $53.28 No ChangeN/A0 $0.02 7/31/2023100 shares $4.00 No ChangeN/A0 $0.04 6/15/20231,600 shares $80.00 -74.6%N/A0 $0.05 5/31/20236,300 shares $693.00 +28.6%N/A0.2 $0.11 5/15/20234,900 shares $489.51 +25.6%N/A0.1 $0.10 4/30/20233,900 shares $1,170.00 No ChangeN/A0.3 $0.30 4/15/20233,900 shares $2,340.00 No ChangeN/A5.6 $0.60 3/31/20233,900 shares $2,272.74 No ChangeN/A2 $0.58 3/15/20233,900 shares $2,496.00 No ChangeN/A0.6 $0.64 2/28/20233,900 shares $2,535.00 No ChangeN/A1.2 $0.65 2/15/20233,900 shares $2,778.75 No ChangeN/A4.9 $0.71 1/31/20233,900 shares $3,705.00 -4.9%N/A0.6 $0.95 1/15/20234,100 shares $3,280.00 No ChangeN/A13.7 $0.80 12/30/20224,100 shares $3,361.80 No ChangeN/A6.8 $0.82 12/15/20224,100 shares $3,485.00 +5.1%N/A2.6 $0.85 11/30/20223,900 shares $2,496.00 -9.3%N/A1.6 $0.64 11/15/20224,300 shares $4,299.57 No ChangeN/A1.3 $1.00 7/31/20223,800 shares $266.76 -76.4%N/A0 $0.07 7/15/202216,100 shares $966.00 -21.5%N/A0.6 $0.06 6/30/202220,500 shares $1,230.00 +169.7%N/A1.2 $0.06 6/15/20227,600 shares $456.00 No ChangeN/A0.3 $0.06 5/15/20223,200 shares $212.80 -59.5%N/A0.1 $0.07 4/30/20227,900 shares $513.50 -4.8%N/A0.1 $0.07 4/15/20228,300 shares $581.00 -58.5%N/A0.3 $0.07 3/31/202220,000 shares $1,380.00 +1,233.3%N/A0.3 $0.07 3/15/20221,500 shares $119.85 -79.5%N/A0 $0.08 2/28/20227,300 shares $481.80 -45.5%N/A0.1 $0.07 2/15/202213,400 shares $1,085.40 +1,388.9%N/A0.1 $0.08 1/31/2022900 shares $89.55 -18.2%N/A0 $0.10 1/15/20221,100 shares $108.90 -8.3%N/A0 $0.10The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. ATRX Short Interest - Frequently Asked Questions What is Adhera Therapeutics' current short interest? Short interest is the volume of Adhera Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 100 shares of ATRX short. Learn More on Adhera Therapeutics' current short interest. Is Adhera Therapeutics' short interest increasing or decreasing? Adhera Therapeutics saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 100 shares, a decrease of 95.0% from the previous total of 2,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Adhera Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Adhera Therapeutics: Amarantus BioScience Holdings, Inc. (0.00%), Propanc Biopharma, Inc. (0.14%), Predictive Technology Group, Inc. (0.00%), GelStat Corp. (0.00%), Acura Pharmaceuticals, Inc. (0.01%), NovAccess Global Inc. (0.01%), Skinvisible, Inc. (0.05%), RenovaCare, Inc. (0.00%), Bruush Oral Care Inc. (286.27%), CVR Medical Corp. (0.03%), and Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Adhera Therapeutics stock? Short selling ATRX is an investing strategy that aims to generate trading profit from Adhera Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Adhera Therapeutics? A short squeeze for Adhera Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ATRX, which in turn drives the price of the stock up even further. How often is Adhera Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATRX, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: AMBS Short Squeeze PPCB Short Squeeze PRED Short Squeeze GSAC Short Squeeze ACUR Short Squeeze XSNX Short Squeeze SKVI Short Squeeze RCAR Short Squeeze DECN Short Squeeze BRSH Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:ATRX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsThe 1,000X Crypto PlaybookTrue Market InsidersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityThe #1 Crypto for AIWeiss RatingsWhy Is Gold On a MASSIVE rally? Huge AlertsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & Company